Trametinib + Azacitidine (JMML)

Current understanding

To be populated as evidence accumulates.

2026-07-20 — Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia: cross-connection with trametinib: Monotherapy trametinib in R/R JMML complements the combination trametinib + azacitidine strategy in newly diagnosed JMML, together mapping the disease-stage positioning of MEK inhibition in JMML. (novelty: 3)
2026-09-04 — A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: Phase I/II trial design registered: newly diagnosed JMML patients receive trametinib + azacitidine, with fludarabine + cytarabine added for high-risk disease; safety and efficacy endpoints; no results yet reported. (novelty: 3)